InterMune to Present at J. P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 6, 2014
BRISBANE, Calif., Jan. 6, 2014 /PRNewswire/ --InterMune, Inc. (NASDAQ: ITMN)
today announced that Dan Welch, Chairman, Chief Executive Officer and
President of InterMune, will present at the 32nd Annual J. P. Morgan
Healthcare Conference in San Francisco on January 13, 2014, at 12:00 Noon EST
/ 9:00 a.m. PST.
To access a live audio webcast of the presentation, investors and other
interested parties may log on to the investors page of InterMune's corporate
website at www.intermune.com. The company recommends logging on to the site
15 minutes prior to the start of the presentation in order to register or
download any necessary software.
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan fibrotic
diseases. In pulmonology, InterMune is focused on therapies for the treatment
of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.
Pirfenidone, the only medicine approved for IPF anywhere in the world, is
approved for marketing by InterMune in the EU and Canada as Esbriet^® and is
currently in a Phase 3 clinical trial to support regulatory registration in
the United States. InterMune's research programs are focused on the discovery
of targeted, small-molecule therapeutics and biomarkers to treat and monitor
serious pulmonary and fibrotic diseases.For additional information about
InterMune and its R&D pipeline, please visit http://www.intermune.com.
SOURCE InterMune, Inc.
Contact: Jim Goff, InterMune, Inc., 415-466-2228, email@example.com
Press spacebar to pause and continue. Press esc to stop.